Purposing Saikosaponins for the treatment of COVID-19

Med Hypotheses. 2020 Jul:140:109782. doi: 10.1016/j.mehy.2020.109782. Epub 2020 Apr 23.

Authors

Eshak I Bahbah¹, Ahmed Negida^{2

3

4}, Mohamed Salah Nabet⁵

Affiliations

¹ School of Medicine, Al-Azhar University, Damietta, Egypt.
² School of Pharmacy and Biological Sciences, University of Portsmouth, UK.
³ School of Medicine, Zagazig University, Sharkia, Egypt.
⁴ Zagazig University Hospitals, Zagazig University, Sharkia, Egypt.
⁵ Department of Pharmaceutics and Industrial Pharmacy, School of Pharmacy, Zagazig University, Sharkia, Egypt.

No abstract available

Publication types

Letter

MeSH terms

Angiotensin-Converting Enzyme 2
Anti-Inflammatory Agents / pharmacology
Anti-Inflammatory Agents / therapeutic use*
Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use*
Betacoronavirus / drug effects*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / complications
Coronavirus Infections / drug therapy*
Cytokine Release Syndrome / drug therapy
Cytokine Release Syndrome / etiology
Drug Repositioning*
Humans
Immunologic Factors / pharmacology
Immunologic Factors / therapeutic use*
Lymphocyte Activation / drug effects
Molecular Docking Simulation
Oleanolic Acid / analogs & derivatives*
Oleanolic Acid / pharmacology
Oleanolic Acid / therapeutic use
Pandemics*
Peptidyl-Dipeptidase A / drug effects
Pneumonia, Viral / complications
Pneumonia, Viral / drug therapy*
Receptors, Virus / drug effects
SARS-CoV-2
Saponins / pharmacology
Saponins / therapeutic use*

Substances

Anti-Inflammatory Agents
Antiviral Agents
Immunologic Factors
Receptors, Virus
Saponins
Oleanolic Acid
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2
saikosaponin D